After zipping into the accelerated approval of its experimental mRNA gene therapy for COVID, Moderna is hoping for the same swift and accelerated approval for its mRNA cancer vaccine, Moderna president Steven Hoge announced at an annual health care conference March 13, 2023. Hoge said he’s banking on both Merck’s and Moderna’s mRNA-4157 cancer vaccine trial data to get them the accelerated green light.
Read more here: https://blogs.mercola.com/sites/vitalvotes/archive/2023/03/13/moderna-looks-to-accelerate-its-cancer-vaccine.aspx
